Physician profile
Timothy Peter Robuck
NPI 1609300953
$440.98
in general payments reported to CMS, 2019-2025
11 companies · $88.68 in 2025
The $88.68 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $72.09 · 2023: $100 · 2024: $180 · 2025: $88.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $196.71 | 2023-2025 | Qulipta, Vraylar |
| Phathom Pharmaceuticals, INC. | $49.55 | 2024 | Voquezna |
| Pfizer INC. | $49.49 | 2022-2024 | |
| Novo Nordisk INC | $30.17 | 2022 | |
| Sumitomo Pharma America, INC. | $24.20 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $19.07 | 2023 | Dificid |
| Ethicon INC. | $17.81 | 2024 | Monarch Platform |
| Exact Sciences Corporation | $14.38 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $13.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Robuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.